NEW YORK (GenomeWeb) – Immunotherapy and companion diagnostic developer Treos Bio said today it has completed an $8 million private investment round.

The new funding will be used to support an early-stage clinical trial of PolyPEPI, a precision immunotherapy vaccine for colorectal cancer. The company expects to begin the trial this year. It plans to use its companion diagnostics to identify patients that could be likely responders to the vaccine.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.